Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardio Protective Effect of Dapagliflozin in Hemodialysis Patients
NCT06759077Phase 3Completed
- Sponsor
- Al-Azhar University
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in chronic kidney disease (CKD), sponsored by Al-Azhar University. Started Feb 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06759077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759077.